Royal Bank Of Canada reissued their outperform rating on shares of Boston Scientific Corp. (NYSE:BSX) in a research report released on Friday morning. Royal Bank Of Canada currently has a $28.00 target price on the stock.

BSX has been the subject of a number of other reports. Jefferies Group boosted their price objective on shares of Boston Scientific Corp. from $21.00 to $24.00 and gave the stock a hold rating in a report on Friday, July 29th. Citigroup Inc. lifted their target price on shares of Boston Scientific Corp. from $26.00 to $28.00 and gave the stock a buy rating in a research note on Wednesday, August 3rd. RBC Capital Markets reaffirmed a buy rating and issued a $28.00 target price on shares of Boston Scientific Corp. in a research note on Friday, July 29th. Zacks Investment Research raised shares of Boston Scientific Corp. from a hold rating to a buy rating and set a $26.00 target price on the stock in a research note on Tuesday, October 4th. Finally, Argus raised shares of Boston Scientific Corp. from a hold rating to a buy rating and lifted their target price for the stock from $23.82 to $33.00 in a research note on Thursday, September 1st. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. Boston Scientific Corp. presently has an average rating of Buy and a consensus target price of $25.19.

Analyst Recommendations for Boston Scientific Corp. (NYSE:BSX)

Boston Scientific Corp. (NYSE:BSX) traded down 0.39% on Friday, hitting $22.86. 1,727,574 shares of the company’s stock were exchanged. Boston Scientific Corp. has a 52-week low of $15.67 and a 52-week high of $24.79. The stock’s market cap is $31.11 billion. The firm has a 50 day moving average price of $23.67 and a 200-day moving average price of $22.70.

Boston Scientific Corp. (NYSE:BSX) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.27 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.27. The firm earned $2.13 billion during the quarter, compared to analyst estimates of $2.05 billion. Boston Scientific Corp. had a negative net margin of 4.34% and a positive return on equity of 22.66%. The business’s quarterly revenue was up 15.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.22 EPS. Analysts predict that Boston Scientific Corp. will post ($0.02) earnings per share for the current fiscal year.

In other Boston Scientific Corp. news, SVP David A. Pierce sold 2,480 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $24.03, for a total value of $59,594.40. Following the completion of the sale, the senior vice president now owns 28,080 shares of the company’s stock, valued at $674,762.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Timothy A. Pratt sold 24,000 shares of the firm’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $24.46, for a total value of $587,040.00. Following the completion of the sale, the executive vice president now directly owns 287,495 shares of the company’s stock, valued at approximately $7,032,127.70. The disclosure for this sale can be found here. 1.31% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the company. National Pension Service increased its stake in shares of Boston Scientific Corp. by 8.6% in the third quarter. National Pension Service now owns 977,146 shares of the company’s stock valued at $23,256,000 after buying an additional 77,539 shares in the last quarter. Private Trust Co. NA increased its stake in shares of Boston Scientific Corp. by 15.6% in the third quarter. Private Trust Co. NA now owns 24,546 shares of the company’s stock valued at $584,000 after buying an additional 3,319 shares in the last quarter. MSI Financial Services Inc increased its stake in shares of Boston Scientific Corp. by 39.2% in the third quarter. MSI Financial Services Inc now owns 5,826 shares of the company’s stock valued at $139,000 after buying an additional 1,640 shares in the last quarter. Gulf International Bank UK Ltd increased its stake in shares of Boston Scientific Corp. by 0.9% in the third quarter. Gulf International Bank UK Ltd now owns 409,215 shares of the company’s stock valued at $9,739,000 after buying an additional 3,500 shares in the last quarter. Finally, Capstone Asset Management Co. increased its stake in shares of Boston Scientific Corp. by 6.2% in the third quarter. Capstone Asset Management Co. now owns 154,832 shares of the company’s stock valued at $3,685,000 after buying an additional 9,054 shares in the last quarter. 92.05% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Corp. Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

5 Day Chart for NYSE:BSX

Receive News & Stock Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related stocks with our FREE daily email newsletter.